 |
|
Oncology
|
|
Our cancer therapy, DM5167, is a second-generation PARP1 selective inhibitor. It is currently undergoing phase 1 clinical trials at four major hospitals in Korea that meet international clinical trial standards. Preclinical data highlight significant advancements of DM5167 over first-generation PARP-inhibitors–in efficacy, toxicity profiles, and blood-brain barrier (BBB) penetration. Compared to AZD5305, AstraZeneca’s PARP1-selective inhibitor in Phase 2 trials, DM5167 demonstrates exceptional hematological toxicity profiles and BBB penetration indicators with the brain-to-plasma concentration ratio (Kp, brain) of 0.89, making it an ideal candidate for combination therapies. DM5167 targets cancer cells with homologous recombination deficiencies (HRD) caused by BRCA mutation and other genetic mutations. It also demonstrates significant potential in treating metastatic brain tumors.
|
|